HeartSciences Q3 cash $7.1M; licenses AI-ECG from Mount Sinai; FDA 510(k) path

HeartSciences Inc.

2024-Q3 EPS reported -$0.19 revenue$18,600

No significant revenue in Q3 FY2024; cash $7.1M, shareholders' equity $8.6M as of Jan 31, 2024.
Raised $9.2M net from stock sales and converted $1.1M debt to equity during quarter.
Licensed AI-ECG algorithms and IP from Icahn School of Medicine at Mount Sinai; Mount Sinai became largest shareholder.
FDA pathway changed to 510(k) for MyoVista device; targeting FDA clearance around calendar year-end 2024.
Peer-reviewed study showed MyoVista AI-ECG outperformed standard screening for heart disease in diabetic patients.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HeartSciences Inc. reported third quarter fiscal 2024 ended January 31, 2024 results: revenue There were no significant revenues in the third quarter fiscal 2024..

Period: third quarter fiscal 2024 ended January 31, 2024
Revenue: There were no significant revenues in the third quarter fiscal 2024.
Result: reported results

Exact text from the filing

HeartSciences Reports Third Quarter Fiscal 2024 Financial Results Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc . d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”) , an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.

View on SEC.gov

Browse all earnings releases →

HeartSciences Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-022613

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.